Current Perspectives on Long-term Obesity Pharmacotherapy

Canadian Journal of Diabetes

Volumn 40, Issue 2, 2016, Pages 184-191

  Wharton, Sean ^a,b  

^a Weight Management and Diabetes   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

Energy homeostasis; Liraglutide; Lorcaserin; Obesity; Orlistat; Weight loss

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; DEXFENFLURAMINE; FENFLURAMINE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; ANTIOBESITY AGENT;

BODY MASS; CANADA; CLINICAL FEATURE; DRUG EFFICACY; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HUMAN; HUNGER; LONG TERM CARE; META ANALYSIS; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SATIETY; SYSTEMATIC REVIEW; WEIGHT REDUCTION; ADULT; PROGNOSIS;

ADULT; ANTI-OBESITY AGENTS; HUMANS; OBESITY; PROGNOSIS;

EID: 84951167202     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2015.07.005     Document Type: Review

References (88)

1. Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C., et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014, 384:766-781.
2. Brauer P., Connor Gorber S., Shaw E., Singh H., Bell N., Shane A.R., et al. Recommendations for prevention of weight gain and use of behavioural and pharmacologic interventions to manage overweight and obesity in adults in primary care. CMAJ 2015, 187:184-195.
3. Gotay C.C., Katzmarzyk P.T., Janssen I., Dawson M.Y., Aminoltejari K., Bartley N.L. Updating the Canadian obesity maps: An epidemic in progress. Can J Public Health 2013, 104:e64-8.
4. Twells L.K., Gregory D.M., Reddigan J., Midodzi W.K. Current and predicted prevalence of obesity in Canada: A trend analysis. CMAJ Open 2014, 2:E18-26.
5. Hu F.B., Manson J.E., Stampfer M.J., Colditz G., Liu S., Solomon C.G., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001, 345:790-797.
6. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., Dietz W.H. The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
7. Allison D.B., Downey M., Atkinson R.L., Billington C.J., Bray G.A., Eckel R.H., et al. Obesity as a disease: A white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring) 2008, 16:1161-1177.
8. Mechanick J.I., Garber A.J., Handelsman Y., Garvey W.T. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract 2012, 18:642-648.
9. Nevill A.M., Stewart A.D., Olds T., Holder R. Relationship between adiposity and body size reveals limitations of BMI. Am J Phys Anthropol 2006, 129:151-156.
10. Janiszewski P.M., Janssen I., Ross R. Does waist circumference predict diabetes and cardiovascular disease beyond commonly evaluated cardiometabolic risk factors?. Diabetes Care 2007, 30:3105-3109.
11. Lau D.C., Douketis J.D., Morrison K.M., Hramiak I.M., Sharma A.M., Ur E., et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007, 176:S1-13.
12. National Institutes of Health Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The Evidence Report. Obes Res 1998, 6(Suppl. 2):51S-209S.
13. Sharma A.M., Kushner R.F. A proposed clinical staging system for obesity. Int J Obes (Lond) 2009, 33:289-295.
14. Kuk J.L., Ardern C.I., Church T.S., Sharma A.M., Padwal R., Sui X., et al. Edmonton obesity staging system: Association with weight history and mortality risk. Appl Physiol Nutr Metab 2011, 36:570-576.
15. Padwal R.S., Pajewski N.M., Allison D.B., Sharma A.M. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 2011, 183:E1059-66.
16. Foster G.D., Wadden T.A., Vogt R.A., Brewer G. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997, 65:79-85.
17. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002, 26(Suppl. 4):S25-8.
18. Van Gaal L.F., Wauters M.A., De Leeuw I.H. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997, 21(Suppl. 1):S5-9.
19. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
20. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
21. Stevens V.J., Obarzanek E., Cook N.R., Lee I.M., Appel L.J., Smith West D., et al. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001, 134:1-11.
22. Expert C., Wharton S., Sharma A.M., Lau D.C. Weight management in diabetes. Can J Diabetes 2013, 37(Suppl. 1):S82-6. Canadian Diabetes Association Clinical Practice Guidelines.
23. Leblanc E.S., O'Connor E., Whitlock E.P., Patnode C.D., Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: A systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:434-447.
24. Wadden T.A., Volger S., Sarwer D.B., Vetter M.L., Tsai A.G., Berkowitz R.I., et al. A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med 2011, 365:1969-1979.
25. Mann T., Tomiyama A.J., Westling E., Lew A.M., Samuels B., Chatman J. Medicare's search for effective obesity treatments: Diets are not the answer. Am Psychol 2007, 62:220-233.
26. Sjostrom L., Narbro K., Sjostrom C.D., Karason K., Larsson B., Wedel H., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752.
27. Padwal R., Klarenbach S., Wiebe N., Birch D., Karmali S., Manns B., et al. Bariatric surgery: A systematic review and network meta-analysis of randomized trials. Obes Rev 2011, 12:602-621.
28. Christou N.V. Access to bariatric (metabolic) surgery in Canada. Can J Diabetes 2011, 35:123-128.
29. Padwal R.S., Chang H.J., Klarenbach S., Sharma A.M., Majumdar S.R. Characteristics of the population eligible for and receiving publicly funded bariatric surgery in Canada. Int J Equity Health 2012, 11:54.
30. Padwal R.S., Damjanovic S., Schulze K.M., Lewanczuk R.Z., Lau D.C., Sharma A.M. Canadian physicians' use of antiobesity drugs and their referral patterns to weight management programs or providers: The SOCCER Study. J Obes 2011, 2011:686521.
31. Guyenet S.J., Schwartz M.W. Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab 2012, 97:745-755.
32. Woods S.C., D'Alessio D.A. Central control of body weight and appetite. J Clin Endocrinol Metab 2008, 93(11 Suppl. 1):S37-50.
33. Grunvald E. Medical management of obesity: A comprehensive review. Clin Obstet Gynecol 2014, 57:465-484.
34. Padwal R.S., Majumdar S.R. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71-77.
35. Schwartz A., Doucet E. Relative changes in resting energy expenditure during weight loss: A systematic review. Obes Rev 2010, 11:531-547.
36. Sumithran P., Prendergast L.A., Delbridge E., Purcell K., Shulkes A., Kriketos A., et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011, 365:1597-1604.
37. Hauptman J.B., Jeunet F.S., Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992, 55(Suppl. 1):S309-13.
38. McNeely W., Benfield P. Orlistat. Drugs 1998, 56:241-249. discussion 250.
39. Hoffmann-La Roche Limited XENICAL product monograph 2005.
40. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003, (4). CD004094.
41. Li Z., Maglione M., Tu W., Mojica W., Arterburn D., Shugarman L.R., et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532-546.
42. Rucker D., Padwal R., Li S.K., Curioni C., Lau D.C. Long-term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ 2007, 335:1194-1199.
43. Finer N., James W.P., Kopelman P.G., Lean M.E., Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000, 24:306-313.
44. Padwal R., Kezouh A., Levine M., Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 2007, 31:1567-1570.
45. Torekov S.S., Madsbad S., Holst J.J. Obesity: An indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev 2011, 12:593-601.
46. Baggio L.L., Drucker D.J. Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight. J Clin Invest 2014, 124:4223-4226.
47. Delgado-Aros S., Kim D.Y., Burton D.D., Thomforde G.M., Stephens D., Brinkmann B.H., et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 2002, 282:G424-31.
48. Holst J.J., Vilsboll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009, 297:127-136.
49. Mentlein R. Dipeptidyl-peptidase IV (CD26): Role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
50. Barrera J.G., Sandoval D.A., D'Alessio D.A., Seeley R.J. GLP-1 and energy balance: An integrated model of short-term and long-term control. Nat Rev Endocrinol 2011, 7:507-516.
51. Jelsing J., Vrang N., Hansen G., Raun K., Tang-Christensen M., Knudsen L.B. Liraglutide: Short-lived effect on gastric emptying, long-lasting effects on body weight. Diabetes Obes Metab 2012, 14:531-538.
52. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002, 18:7-14.
53. Secher A., Jelsing J., Baquero A.F., Hecksher-Sorensen J., Cowley M.A., Dalboge L.S., et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014, 124:4473-4488.
54. Astrup A., Carraro R., Finer N., Harper A., Kunesova M., Lean M.E., et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012, 36:843-854.
55. Astrup A., Rossner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., et al. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
56. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160:909-917.
57. Vilsboll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: Systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771.
58. Katout M., Zhu H., Rutsky J., Shah P., Brook R.D., Zhong J., et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014, 27:130-139.
59. Robinson L.E., Holt T.A., Rees K., Randeva H.S., O'Hare J.P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open 2013, 3. pii: e001986.
60. Novo Nordisk Inc SAXENDA US prescribing information 2015.
61. Novo Nordisk Canada Inc SAXENDA (liraglutide) product monograph 2015.
62. Davies M., Bode B.W., Kushner R.F., Lewin A.J., Skjoth T.V., Jensen C.B., et al. Liraglutide 3.0 mg for weight management in obese/overweight adults with type 2 diabetes: Results from the SCALE Diabetes 56-week randomized, double-blind, placebo-controlled trial [Abstract]. 2014;(97-OR). Diabetes 2014, 63(Suppl. 1):A26.
63. Wadden T.A., Hollander P., Klein S., Niswender K., Woo V., Hale P.M., et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE maintenance randomized study. Int J Obes (Lond) 2013, 37:1443-1451.
64. Proietto J., le Roux C.W., Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: The SCALE obesity and prediabetes, a randomised, double-blind and placebo-controlled trial [Abstract]. Obes Res Clin Pract 2014, 8(Suppl. 1):117.
65. Blackman A., Foster G., Zammit G., Rosenberg R., Aronne L., Wadden T., et al. Liraglutide 3.0 mg reduces severity of obstructive sleep apnoea and body weight in obese individuals: SCALE sleep apnoea trial [Abstract]. Diabetologia 2014, 57(Suppl. 1):S85.
66. Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015, 373:11-22.
67. ClinicalTrials.gov The effects of exenatide (byetta) on energy expenditure and weight loss in nondiabetic obese subjects 2014, ClinicalTrials.gov Identifier: NCT00856609.
68. Lam D.D., Garfield A.S., Marston O.J., Shaw J., Heisler L.K. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav 2010, 97:84-91.
69. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.D., Edwards B.S., Edwards W.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 337:581-588.
70. U.S.Food and Drug Administration (FDA) FDA drug safety communication: FDA recommends against the continued use of meridia (sibutramine) 2010.
71. Burke L.K., Doslikova B., D'Agostino G., Garfield A.S., Farooq G., Burdakov D., et al. 5-HT obesity medication efficacy via POMC activation is maintained during aging. Endocrinology 2014, 155:3732-3738.
72. Halford J.C., Harrold J.A., Boyland E.J., Lawton C.L., Blundell J.E. Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Drugs 2007, 67:27-55.
73. Arena Pharmaceuticals BELVIQ (lorcaserin HCl) US prescribing information 2014.
74. Fidler M.C., Sanchez M., Raether B., Weissman N.J., Smith S.R., Shanahan W.R., et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab 2011, 96:3067-3077.
75. Smith S.R., Weissman N.J., Anderson C.M., Sanchez M., Chuang E., Stubbe S., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010, 363:245-256.
76. Bray G.A., Ryan D.H. Update on obesity pharmacotherapy. Ann N Y Acad Sci 2014, 1311:1-13.
77. Meldrum B.S. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996, 37(Suppl. 6):S4-11.
78. VIVUS Inc QSYMIA (phentermine and topiramate extended-release) tablets US Prescribing Information 2012.
79. Wolfe S.M. When EMA and FDA decisions conflict: Differences in patients or in regulation?. BMJ 2013, 347:f5140.
80. Allison D.B., Gadde K.M., Garvey W.T., Peterson C.A., Schwiers M.L., Najarian T., et al. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012, 20:330-342.
81. Gadde K.M., Allison D.B., Ryan D.H., Peterson C.A., Troupin B., Schwiers M.L., et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:1341-1352.
82. Garvey W.T., Ryan D.H., Look M., Gadde K.M., Allison D.B., Peterson C.A., et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012, 95:297-308.
83. Greenway F.L., Whitehouse M.J., Guttadauria M., Anderson J.W., Atkinson R.L., Fujioka K., et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009, 17:30-39.
84. Lee M.W., Fujioka K. Naltrexone for the treatment of obesity: Review and update. Expert Opin Pharmacother 2009, 10:1841-1845.
85. Greenway F.L., Fujioka K., Plodkowski R.A., Mudaliar S., Guttadauria M., Erickson J., et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010, 376:595-605.
86. Apovian C.M., Aronne L., Rubino D., Still C., Wyatt H., Burns C., et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013, 21:935-943.
87. Wadden T.A., Foreyt J.P., Foster G.D., Hill J.O., Klein S., O'Neil P.M., et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity (Silver Spring) 2011, 19:110-120.
88. Orexigen Therapeutics I Cardiovascular outcomes study of naltrexone sr/bupropion sr in overweight and obese subjects with cardiovascular risk factors (the Light Study) 2014, [updated May 20, 2014]. NLM identifier: NCT01601704. ClinicalTrials.gov.